Ligand Pharmaceuticals, Inc.

Tularik Limited

Glenn E Croston

David V Goeddel

Zhaodan Cao

Johan Auwerx

Stephen G Miller

Michael R Briggs

Bart Staels

Piet De Vos

This invention relates to the isolation and cloning of the promoter and other control regions of a human ob gene. It provides a method for identifying and screening for agents useful for the treatment of diseases and pathological conditions affected by the level of expression of an ob gene. These agents interact directly or indirectly with the promoter or other control regions of the ob gene. A PPAR.gamma. agonist, BRL49653, has been identified to be useful in treating anorexia, cachexia, and other diseases characterized by insufficient food intake or body weight loss. Modulators of ob gene expression may be used to treat other diseases such as obesity, diabetes, hypertension, cardiovascular diseases and infertility.

Modulators of ob gene and screening methods therefor

The invention relates to human Interleukin-1 Receptor-Associated Protein Kinases (IRAKs), nucleic acids which encode IRAKs and hybridization probes and primers capable of hybridizing with IRAK genes and methods of using the subject compositions; in particular, methods such as IRAK-based in vitro binding assays and phosphorylation assays for screening chemical libraries for lead compounds for pharmacological agents.

Interleukin-1 receptor-associated protein kinase and assays

Growing community of inventors

San Diego, CA, United States of America

Glenn E Croston